Selected Publications

Braghiroli MI, Sabbaga J, Hoff PM. Bevacizumab: overview of the literature. Expert Rev Anticancer Ther. 2012 May;12(5):567-80. PMID: 22594892.
doi: 10.1586/era.12.13 

Doki, Y., Ajani, J. A., Kato, K., Xu, J., Wyrwicz, L., Motoyama, S., Ogata, T., Kawakami, H., Hsu, C.-H., Adenis, A., El Hajbi, F., Di Bartolomeo, M., Braghiroli, M. I., et al. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. New England Journal of Medicine, 2022, 386(5), 449–462.
doi: 10.1056/NEJMoa2111380 

Tabernero J, Van Cutsem E, Bang Y-J, Fuchs CS, Wyrwicz L, Lee KW, Kubada I, Garrido M, Chung HC, Salguero HRC, Mansoor W, Braghiroli MIFM, et al. Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study. Journal of Clinical Oncology. 2019 Jun 20;37(18_suppl):LBA4007–7.
doi: 10.1200/JCO.2019.37.18_suppl.LBA4007 

Connell LC, Mota JM, Braghiroli MI, Hoff PM. The Rising Incidence of Younger Patients With Colorectal Cancer: Questions About Screening, Biology, and Treatment. Curr Treat Options Oncol. 2017 Apr;18(4):23. PMID: 28391421.
doi: 10.1007/s11864-017-0463-3 

Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Lee J, Castro HR, Mansoor W, Braghiroli MI, et al. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020 Oct 1;6(10):1571-1580. PMID: 32880601; PMCID: PMC7489405.
doi: 10.1001/jamaoncol.2020.3370